Published in Acta Naturae on October 01, 2009
Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis. Int J Biomed Sci (2013) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (1997) 23.92
Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol (2006) 7.75
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med (2002) 4.02
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One (2007) 3.96
CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med (2001) 3.51
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet (2005) 2.82
Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol (2003) 2.21
The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol (2002) 2.15
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet (2001) 2.11
Type I interferon: potential therapeutic target for psoriasis? PLoS One (2008) 2.08
Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum (2005) 2.05
Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol (2007) 1.94
The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet (2004) 1.76
Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals. J Mol Med (Berl) (2005) 1.62
Psoriasis: epidemiology. Clin Dermatol (2007) 1.56
Immunopathogenesis of psoriasis. Exp Dermatol (2007) 1.44
Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem (2006) 1.42
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet (2002) 1.42
Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J (2001) 1.34
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis (2003) 1.31
Fine mapping of the psoriasis susceptibility locus PSORS1 supports HLA-C as the susceptibility gene in the Han Chinese population. PLoS Genet (2008) 1.26
The genetics of psoriasis and autoimmunity. Annu Rev Genomics Hum Genet (2005) 1.25
Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J (2002) 1.24
The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. J Invest Dermatol (2005) 1.22
Psoriasis--clinical features. Br Med J (1971) 1.17
Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol (2003) 1.13
[Pharmacological metrology]. Izv Akad Nauk SSSR Biol (1990) 1.12
Psoriasis, polymorphonuclear leukocytes, and lithium carbonate. An important clue. Arch Dermatol (1979) 1.11
Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. J Invest Dermatol (2002) 1.05
Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin Exp Dermatol (2005) 1.01
Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol (2008) 0.98
Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol (1987) 0.97
Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol (2001) 0.91
Genetic aspects of psoriasis. Clin Exp Dermatol (2001) 0.86
Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol (2009) 0.86
[Role of transcription factor AP-1 in integration of cellular signalling systems]. Mol Biol (Mosk) (2007) 0.83
Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. J Invest Dermatol (1986) 0.83
Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J Immunol (1998) 0.82
Genome-wide studies of psoriasis susceptibility loci: a review. J Dermatol Sci (2004) 0.80
Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica (1990) 0.79
A novel c.-22T>C mutation in GALK1 promoter is associated with elevated galactokinase phenotype. BMC Med Genet (2009) 0.78
Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol (1988) 0.77
[Population analysis and determination of the ethnic background are necessary in the study of multifactorial diseases: a study using the Dagestan population as a model]. Genetika (2006) 0.77
IgG class antibodies to heat shock-induced streptococcal antigens in psoriatic patients. Int J Dermatol (2003) 0.77
Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2007) 0.77
[Transcription factor AP-1 components as a psoriasis candidate genes]. Mol Biol (Mosk) (2008) 0.76
[Expression of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis]. Genetika (2011) 0.85
Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer. Bull Exp Biol Med (2014) 0.83
Comparative study of the expression of ATF-3 and ATF-4 genes in vessels involved into atherosclerosis process and in psoriatic skin. Bull Exp Biol Med (2011) 0.78
[The comparative analysis of psoriasis and Crohn disease molecular-genetical processes under pathological conditions]. Mol Biol (Mosk) (2009) 0.78
[Lactoferrin and fibrinogen degradation products in saliva]. Lab Delo (1991) 0.77
[Population analysis and determination of the ethnic background are necessary in the study of multifactorial diseases: a study using the Dagestan population as a model]. Genetika (2006) 0.77
[Protein buffer in human mixed saliva]. Stomatologiia (Mosk) (1985) 0.76
[Transcription factor AP-1 components as a psoriasis candidate genes]. Mol Biol (Mosk) (2008) 0.76
[Serum lactoferrin level in normal conditions and in pathology]. Vopr Med Khim (1990) 0.76
[The role of peptidyl-prolyl-Cis/trans-isomerase Genes of Arabidopsis thaliana in plant defense during the course of Xanthomonas campestris infection]. Genetika (2014) 0.76
[The molecular genetics of psoriasis]. Vestn Ross Akad Med Nauk (2006) 0.76
[Iron and nonheme iron protein metabolism in ejaculates with varying degrees of fertility]. Urol Nefrol (Mosk) (1998) 0.75
[Genetic markers and psoriasis in three ethnic populations of Dagestan]. Genetika (2005) 0.75
Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis. Int J Biomed Sci (2013) 0.75
[Human salivary lactoferrin--a new health status index]. Stomatologiia (Mosk) (1995) 0.75
[Study of salivary lactoferrin in prophylactic examinations]. Klin Lab Diagn (1996) 0.75
[Results of complex medical examination of workers engaged in the construction of the western sector of the Baĭkal-Amur railroad]. Sov Med (1976) 0.75
[Biological activity of the cell walls of NAG-vibrios]. Mikrobiol Zh (1974) 0.75
[Contralateral donor kidney study for predicting the fate of transplants in the recipient body]. Vestn Khir Im I I Grek (1979) 0.75
[Transplantation of the pancreas in clinical practice (review of the literature)]. Khirurgiia (Mosk) (1987) 0.75
[Crystalline L-asparaginase from Proteus vulgaris]. Prikl Biokhim Mikrobiol (1977) 0.75
[Lactoferrin and leukocytes in the blood of oncologic patients]. Lab Delo (1990) 0.75
[Ejaculate microflora sensitivity to lactoferrin in chronic prostatitis]. Urologiia (2004) 0.75
[Epidemiology of primary liver cancer in the Belarus Republic]. Vopr Onkol (1998) 0.75
[The potentials of gastric biopsy in the diagnosis of dysplasia and cancer of the stomach]. Vopr Onkol (1989) 0.75
[Medium molecular weight molecules and their fractions in Astrakhan rickettsial fever]. Klin Lab Diagn (1999) 0.75
[Polyvalent cultural foot-and-mouth disease vaccine]. Veterinariia (1977) 0.75
[Expression of the FOSL1 gene in psoriasis and atherosclerosis]. Genetika (2010) 0.75
[Association of NAT2 polymorphism with risks to develop psoriasis and various dermatological diseases in Moscow population]. Mol Biol (Mosk) (2009) 0.75
[Prostatic cancer: immunochemical control over chemotherapy]. Urologiia (2001) 0.75
[Means for decreasing the incidence of postoperative tubular necrosis in kidney transplants]. Vestn Khir Im I I Grek (1987) 0.75
[Formation of interpolymer complexes with human seminal plasma proteins]. Vopr Med Khim (1990) 0.75
[Expression of bioinformatically identified genes in skin of psoriasis patients]. Genetika (2013) 0.75
[Immuno-chemical and physico-chemical properties of human prostatic beta-globulin]. Vopr Med Khim (1990) 0.75
[Carbohydrate metabolism in the materno-fetus system under normal conditions and in hypoxia]. Akush Ginekol (Mosk) (1983) 0.75
[The nature of the antigenic restructuring of tumors of the human prostate]. Vopr Onkol (1988) 0.75
[Acute phase proteins in the diagnosis of prostatic neoplasms]. Lab Delo (1981) 0.75
[Role of receptor for advanced glycation end-products in pathgenesis of psoriasis]. Mol Biol (Mosk) (2014) 0.75
[The role of non-invasive diagnostics of pulmonary embolism in the optimization of treatment]. Klin Med (Mosk) (2005) 0.75
[The protein spectrum of ejaculates with different fertilities]. Urol Nefrol (Mosk) (1998) 0.75
[Effect of the main disease and anticoagulant therapy on pulmonary artery thromboembolism]. Voen Med Zh (2006) 0.75
[Selenium correction of male subfertility]. Urologiia (2000) 0.75
[Immunochemical and physico-chemical characteristics of lactoferrin in human body fluids]. Vopr Med Khim (1985) 0.75
[Effect of Chlamydia trachomatis lipopolysaccharides on sperm apoptosis and development of male infertility]. Urologiia (2014) 0.75
[Production of placental-type alkaline phosphatase isoenzyme in periapical granuloma]. Stomatologiia (Mosk) (1987) 0.75
[Genetic diversity of local spring soft wheats (Triticum aestivum L.) of west and east Siberia in gliadin genes]. Genetika (2009) 0.75
[PARAMETERS OF SPERMATOGENESIS IN MEN EXPOSED TO DIFFICULT ENVIRONMENTS]. Urologiia (2016) 0.75
[Reaction of the vaso-muscular structures of the extremities to the action of magnetic fields]. Vopr Kurortol Fizioter Lech Fiz Kult (1988) 0.75
[Method of obtaining the maximal amount of fetal blood for laboratory purposes]. Lab Delo (1976) 0.75
[Lead in animals and man (review)]. Gig Sanit (1993) 0.75
[Treatment tactics of patients with pyloroduodenal stenoses]. Khirurgiia (Mosk) (2007) 0.75
[The proteins of human mixed saliva in galvanism and yeast-induced stomatitis]. Stomatologiia (Mosk) (1990) 0.75
[Organ-specific human prostate beta-globulin during tumor growth]. Biull Eksp Biol Med (1980) 0.75
[Determination of the medium molecular level in the evaluation of the effectiveness of quantum hemotherapy in uveitis]. Vestn Oftalmol (1990) 0.75
[Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping]. Genetika (2006) 0.75
[Treatment of gastrointestinal hemorrhage in patients following kidney transplant]. Vestn Khir Im I I Grek (1984) 0.75
[Evaluation of the functional adequacy of a kidney transplant in the body of the donor]. Khirurgiia (Mosk) (1984) 0.75
[Diagnostic value of seminal bactericidal activity in bacteria carriers]. Klin Lab Diagn (2009) 0.75
[Effect of blood transfusions on the survival of cadaveric kidney transplants]. Gematol Transfuziol (1988) 0.75
Preparation and properties of Clostridium thermocellum lichenase deletion variants and their use for construction of bifunctional hybrid proteins. Biochemistry (Mosc) (2000) 0.75
[Problems in obtaining viable donor kidneys for transplantation (review of the literature)]. Khirurgiia (Mosk) (1979) 0.75
[Relation of the survival of kidney transplants to their initial functional integrity]. Vestn Khir Im I I Grek (1980) 0.75
[Use of glucose solutions in the prevention and treatment of fetal hypoxia]. Akush Ginekol (Mosk) (1985) 0.75
[Isolation and properties of specific trypsin inhibitor from human seminal plasma]. Biokhimiia (1990) 0.75
[Apical granulomas--foci of active inflammation]. Stomatologiia (Mosk) (1989) 0.75
[Immunochemical tests in the diagnosis of diseases of the male reproductive system]. Urol Nefrol (Mosk) (1992) 0.75
[Lactoferrin assay in urethritis and urethral prostatitis]. Urologiia (2003) 0.75
[The calculation and regulation of dust exposure doses to decrease the level of occupational diseases of dust etiology]. Med Tr Prom Ekol (1995) 0.75
[Identification of functionally significant mutations in NAT2 gene using biological microchips]. Mol Biol (Mosk) (2007) 0.75
[Production of highly active hyperimmune sera against the foot-and-mouth disease virus]. Veterinariia (1975) 0.75
[Genetically modified animals as model systems of psoriasis]. Mol Biol (Mosk) (2015) 0.75
[Stroma formation in epithelial malignant tumors]. Arkh Patol (1975) 0.75
[Genetically predetermined limitation in the use of HaCaT cells that affects their ability to serve as an experimental model of psoriasis]. Genetika (2014) 0.75
[Treatment of fetal hypoxia with glucose solutions]. Sov Med (1986) 0.75
[The enzymatic activity of the seminal plasma in ejaculates of different fertilities]. Urol Nefrol (Mosk) (1997) 0.75
[The efficacy of hepatotropic agent Remaxol in oncological patients with postoperative liver dysfunction]. Eksp Klin Farmakol (2013) 0.75
[Antigen content in the seminal plasma in male sterility]. Vestn Dermatol Venerol (1982) 0.75
[Prevalence of arterial hypertension among rural population of the Irkutsk region]. Sov Med (1990) 0.75
[Oxalosis of kidney allotransplant]. Urol Nefrol (Mosk) (1982) 0.75